[go: up one dir, main page]

WO2010048365A3 - Therapeutic peptide bioconjugates - Google Patents

Therapeutic peptide bioconjugates Download PDF

Info

Publication number
WO2010048365A3
WO2010048365A3 PCT/US2009/061604 US2009061604W WO2010048365A3 WO 2010048365 A3 WO2010048365 A3 WO 2010048365A3 US 2009061604 W US2009061604 W US 2009061604W WO 2010048365 A3 WO2010048365 A3 WO 2010048365A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory
eye
pharmaceutical composition
therapeutic peptide
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/061604
Other languages
French (fr)
Other versions
WO2010048365A2 (en
Inventor
Stephen P. Massia
Gholam Reza Ehteshami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skysong Innovations LLC
Original Assignee
Arizona Science and Technology Enterprises LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona Science and Technology Enterprises LLC filed Critical Arizona Science and Technology Enterprises LLC
Publication of WO2010048365A2 publication Critical patent/WO2010048365A2/en
Publication of WO2010048365A3 publication Critical patent/WO2010048365A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides for therapeutic bioconjugates comprising a bioselective peptide conjugated to a low-adhesion moiety, that is capable of selectively targeting a ligand of inflammatory tissues. A particular embodiment provides for pharmaceutical composition including an ICAM-I -binding, anti-inflammatory peptide/dextran bioconjugate useful, for example, for limiting inflammatory cell adhesion in the eye. The pharmaceutical composition may be formulated in a topical or injectable medicament for the treatment of inflammation, particularly inflammation of the eye.
PCT/US2009/061604 2008-10-23 2009-10-22 Therapeutic peptide bioconjugates Ceased WO2010048365A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10775408P 2008-10-23 2008-10-23
US61/107,754 2008-10-23

Publications (2)

Publication Number Publication Date
WO2010048365A2 WO2010048365A2 (en) 2010-04-29
WO2010048365A3 true WO2010048365A3 (en) 2010-07-08

Family

ID=42119973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/061604 Ceased WO2010048365A2 (en) 2008-10-23 2009-10-22 Therapeutic peptide bioconjugates

Country Status (1)

Country Link
WO (1) WO2010048365A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9988568B2 (en) 2015-01-30 2018-06-05 Ecolab Usa Inc. Use of anti-agglomerants in high gas to oil ratio formations
US20180256690A1 (en) * 2015-09-15 2018-09-13 University Of Southern California Protection and sealing of the ocular surface barrier by clusterin
CN112315863B (en) * 2020-11-10 2021-12-03 山东百奥生物医药有限公司 Composition for relieving pain and heat sensation in photoelectricity operation and preparation method and application thereof
CN115607686A (en) * 2021-07-14 2023-01-17 广州中医药大学(广州中医药研究院) Catalase-encapsulated nanoparticles and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040028648A1 (en) * 1998-12-30 2004-02-12 The Children's Medical Center Corporation Prevention and treatment of retinal ischemia and edema
US20040127416A1 (en) * 2002-11-15 2004-07-01 Massia Stephen P. Therapeutic bioconjugates
US6849612B2 (en) * 1993-01-21 2005-02-01 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US20060241022A1 (en) * 2004-10-06 2006-10-26 Bowen Benjamin P Selectin targeting bioconjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849612B2 (en) * 1993-01-21 2005-02-01 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US20040028648A1 (en) * 1998-12-30 2004-02-12 The Children's Medical Center Corporation Prevention and treatment of retinal ischemia and edema
US20040127416A1 (en) * 2002-11-15 2004-07-01 Massia Stephen P. Therapeutic bioconjugates
US20060241022A1 (en) * 2004-10-06 2006-10-26 Bowen Benjamin P Selectin targeting bioconjugates

Also Published As

Publication number Publication date
WO2010048365A2 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
WO2009025763A3 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
WO2008116195A3 (en) Compositions comprising an sglt2 ingibitor for treating obesity
WO2007093183A3 (en) Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
WO2007073486A3 (en) Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
WO2010070675A3 (en) Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof
WO2010062581A3 (en) A botanical composition for enhanced skin repair and uses thereof
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
WO2007134245A3 (en) Elastin-like polymer delivery vehicles
WO2006108405A3 (en) Nanoparticle/active ingredient conjugate
WO2011048390A3 (en) Gadd45beta targeting agents
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
WO2010065950A3 (en) Albumin binding peptide-mediated disease targeting
AR053651A1 (en) COMBINED TREATMENT OF ANTIBODY ANTICTLA4 R AROMATASE INHIBITOR FOR BREAST CANCER
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
EP2478894A3 (en) Compositions for treating esophageal disorders
MX2009011900A (en) Diabetic wound healing.
WO2007048019A3 (en) Delivery system for diagnostic and therapeutic agents
CY1109733T1 (en) USE OF POLYTHYLENE GLYCLIS FOR THE TREATMENT OF DISEASES AND INJURIES, DIAGNOSIS
WO2010048365A3 (en) Therapeutic peptide bioconjugates
WO2012040295A3 (en) Therapeutic applications of smad7
WO2010042500A3 (en) Heat shock protein 90 inhibitors, methods of preparing same, and methods for their use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09822681

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09822681

Country of ref document: EP

Kind code of ref document: A2